Literature DB >> 9310010

The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.

P R Donald1, F A Sirgel, F J Botha, H I Seifart, D P Parkin, M L Vandenplas, B W Van de Wal, J S Maritz, D A Mitchison.   

Abstract

Collections of sputum from 105 patients with newly diagnosed pulmonary tuberculosis were made before and at 1 and 2 d after the start of chemotherapy with isoniazid (INH) alone given to groups of patients in doses of 600 mg, 300 mg, 150 mg, 75 mg, 37.5 mg, 18.75 mg, and 9 mg daily, as well as from an untreated group. Counts of colony forming units (cfu) of Mycobacterium tuberculosis in the collections were set up on plates of selective 7H10 medium. The early bactericidal activity (EBA) of INH was defined as the decrease in log10 cfu/ml sputum/day during the first 2 d of treatment. A smooth curve relating EBA to log dose was obtained, with 600 mg INH yielding the highest mean EBA of 0.539, and 18.75 mg INH yielding the lowest EBA (0.111) that could be distinguished from the bactericidal activity of the untreated group. The ratio of the usual dose of 300 mg INH to the lowest dose, of 18.75 mg, that produced a detectable EBA, termed the therapeutic margin, was therefore 16, in contrast to the lower therapeutic margin of 4 for rifampin. The EBA was related to the INH acetylator genotype of patients treated with 600 mg or 9 mg INH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310010     DOI: 10.1164/ajrccm.156.3.9609132

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  45 in total

1.  Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.

Authors:  R S Wallis; M Phillips; J L Johnson; L Teixeira; L M Rocha; E Maciel; L Rose; C Wells; M Palaci; R Dietze; K Eisenach; J J Ellner
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

Review 3.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

4.  Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.

Authors:  Hongmei Yang; Anthony Enimil; Fizza S Gillani; Sampson Antwi; Albert Dompreh; Antoinette Ortsin; Eugene Adu Awhireng; Maxwell Owusu; Lubbe Wiesner; Charles A Peloquin; Awewura Kwara
Journal:  Pediatr Infect Dis J       Date:  2018-01       Impact factor: 2.129

Review 5.  Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis.

Authors:  Kelly E Dooley; Carole D Mitnick; Mary Ann DeGroote; Ekwaro Obuku; Vera Belitsky; Carol D Hamilton; Mamodikoe Makhene; Sarita Shah; James C M Brust; Nadza Durakovic; Eric Nuermberger
Journal:  Clin Infect Dis       Date:  2012-05-21       Impact factor: 9.079

6.  Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis.

Authors:  Moises Palaci; Reynaldo Dietze; David Jamil Hadad; Fabiola Karla Corrêa Ribeiro; Renata Lyrio Peres; Solange Alves Vinhas; Ethel Leonor Noia Maciel; Valdério do Valle Dettoni; Libby Horter; W Henry Boom; John L Johnson; Kathleen D Eisenach
Journal:  J Clin Microbiol       Date:  2007-10-10       Impact factor: 5.948

7.  Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Authors:  L Lalande; L Bourguignon; S Bihari; P Maire; M Neely; R Jelliffe; S Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

8.  Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Authors:  Maxwell T Chirehwa; Helen McIlleron; Lubbe Wiesner; Dissou Affolabi; Oumou Bah-Sow; Corinne Merle; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

9.  Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014.

Authors:  Argita D Salindri; Rose-Marie F Sales; Lauren DiMiceli; Marcos C Schechter; Russell R Kempker; Matthew J Magee
Journal:  Ann Am Thorac Soc       Date:  2018-03

10.  Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Radha K Shandil; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharath; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.